Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Dusseldorf - Delayed Quote EUR

Akeso Inc (4RY.DU)

Compare
8.70
-0.05
(-0.57%)
As of 12:30:21 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4RY.DU

Recent News: 4RY.DU

View More
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
PR Newswire 4 days ago
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
CNN Business 5 days ago

Q4 2024 Summit Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents 6 days ago
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
PR Newswire 6 days ago
Exploring 3 High Growth Tech Stocks with Potential Expansion

Exploring 3 High Growth Tech Stocks with Potential Expansion
Simply Wall St. 10 days ago
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
PR Newswire 10 days ago
3 Prominent Stocks Estimated To Be Undervalued In February 2025

3 Prominent Stocks Estimated To Be Undervalued In February 2025
Simply Wall St. 11 days ago
Top Growth Companies With Insider Ownership In February 2025

Top Growth Companies With Insider Ownership In February 2025
Simply Wall St. 12 days ago
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
PR Newswire 17 days ago
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC

Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
PR Newswire 18 days ago
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC

Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
PR Newswire 25 days ago
View More

Related Tickers

AGTX Agentix Corp.
0.0820
0.00%
 
G28.F Tevogen Bio Holdings Inc.
1.1700
0.00%
 
IVBIY Innovent Biologics Inc.
19.15
0.00%
 
TVGNW Tevogen Bio Holdings Inc.
0.0668
+11.33%
 
PCSA Processa Pharmaceuticals, Inc.
0.5490
+3.58%
 
GLPG.AS Galapagos NV
25.36
+1.52%
 
JUNS Jupiter Neurosciences, Inc.
0.6510
-2.69%
 
IGMS IGM Biosciences, Inc.
1.3600
+1.49%
 
HCWB HCW Biologics Inc.
0.3802
+0.32%
 
OSTX OS Therapies Incorporated
1.6500
+0.61%